Paracetamol Polpharma

Quick links

Choose a section

Quick links to important sections

Advertisements

Paracetamol Polpharma

Advertisements
Advertisements

Overview of Paracetamol Polpharma

Here is a quick overview of Paracetamol Polpharma:

Property Description
Active Ingredient Paracetamol (INN) / Acetaminophen
Common Forms Tablets, Syrup, Suppositories (Varies by product)
Pharmacological Class Analgesic and Antipyretic
Common Use Symptomatic relief of mild-to-moderate pain and fever
Origin Synthetic (Chemically manufactured)

What Type of Medicine is Paracetamol Polpharma and What is it Used For?

Paracetamol Polpharma is a widely used medication categorized as an analgesic (pain reliever) and an antipyretic (fever reducer). It belongs to the pharmacological class of non-opioid pain and fever agents and is clinically recognized for its reliable efficacy in managing common discomfort. The primary purpose of this medicine is to offer symptomatic relief from common discomforts, such as various types of headaches and muscular aches, and to reduce elevated body temperature often associated with viral infections.

The effectiveness of paracetamol for these general uses is well-documented. Paracetamol is recognized as a cornerstone drug for treating pain and fever across all age groups. Furthermore, it is an active substance with established efficacy for treating pain and fever. This status is reflected in the drug’s established reputation in medical guidance.


Understanding the Key Component and Brand Context

The sole active component in Paracetamol Polpharma is the International Nonproprietary Name (INN) substance, paracetamol (or acetaminophen), which is chemically synthesized. This defining ingredient is responsible for the medication's therapeutic effects. Paracetamol Polpharma, as a specific product, is manufactured by Polpharma, a recognized pharmaceutical company, and is typically positioned as an accessible, general-purpose pain and fever reliever in the European market. This synthetic compound is manufactured to be available in various oral forms, such as standard tablets or syrups, to allow for simple ingestion.

Advertisements

What side effects are possible with Paracetamol Polpharma?

Official Classification of Possible Side Effects

The safety profile of paracetamol (acetaminophen), the active substance in this medicine, is officially documented through established regulatory classifications. At recommended therapeutic doses, most adverse reactions are categorized as Rare or Very Rare, according to European Summary of Product Characteristics (SmPC) standards. There are no adverse reactions listed in the Very Common or Common frequency categories.

Documented System-Organ Effects and Serious Risks

Adverse reactions may affect several system-organ classes. Documented effects primarily involve the Hepatobiliary Disorders (liver and bile duct), Blood and Lymphatic System Disorders, Immune System Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious adverse reactions, though infrequent, are explicitly highlighted in regulatory labeling due to their severity. These include hepatic necrosis and potential liver failure, which are the most critical risks and are predominantly associated with overdose. Other serious documented reactions include severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS), and serious blood dyscrasias, such as agranulocytosis.

Safety Constraints and Population Considerations

The regulatory safety profile requires strict adherence to limitations concerning co-administration. The risk of accidental overdose is significantly increased by concomitant use with any other product containing paracetamol, and this practice is officially prohibited.

Safety considerations for special populations are also specified in labeling. Patients with severe hepatic impairment, severe renal impairment, chronic alcohol abuse, or chronic malnutrition are explicitly identified as having an increased risk of toxicity, which requires careful application based on official guidance. Furthermore, prolonged, high-dose use is officially associated with an increased risk of certain renal effects and an enhancement of the effect of oral anticoagulants (leading to increased bleeding risk).

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Urgent Medical Help

Immediate medical attention must be sought in the event of an overdose, even if you feel well. Paracetamol overdose carries a risk of delayed, serious liver damage, which may be fatal or necessitate a liver transplant.

Symptoms of Overdose

Symptoms of a paracetamol overdose generally develop within the first 24 hours and may include:

  • Early Signs: Nausea, vomiting, pallor, lack of appetite (anorexia), and abdominal pain. Some individuals may experience no initial symptoms.
  • Delayed Signs (24 to 72 hours): Clinical signs of liver injury, potentially progressing to hepatic failure, which can involve jaundice, encephalopathy, cerebral oedema, bleeding, and coma. Acute renal failure may also occur.

High-Risk Factors

Liver damage may occur after a single overdose, especially in adults who have taken 10 g or more. The risk is significantly increased in certain patient groups and circumstances, which include:

  • Elderly subjects and young children.
  • Patients with chronic alcoholism or pre-existing liver disease.
  • Individuals with chronic malnutrition or other forms of glutathione depletion.

Emergency Procedure

If an overdose is suspected, immediate transfer to a hospital is essential for medical assessment. Emergency treatment involves measuring the plasma paracetamol concentration and administering the antidote, N-acetylcysteine (NAC), as quickly as possible. The antidote is most effective when given within eight to ten hours of the overdose. Activated charcoal may also be considered in the first hour following ingestion to reduce absorption.

Advertisements

Therapeutic Uses of Paracetamol Polpharma

What Paracetamol Polpharma Treats: Main Uses and Benefits

Paracetamol Polpharma is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to physical discomfort that are classified as mild to moderate pain, such as tension headaches, toothaches, general muscular aches, and discomfort following minor procedures. Acetaminophen is generally applied in settings marked by temporary systemic discomfort.

The medication is applied in addressing symptoms related to systemic imbalance, such as elevated body temperature (fever), a key manifestation of many conditions. It is relevant for easing symptoms that create noticeable physiological strain, such as the generalized body aches and malaise that accompany conditions involving episodic or fluctuating manifestations like colds and influenza. It offers symptomatic relief that supports the patient during difficult episodes by easing distress when symptom clusters may appear suddenly or fluctuate.

It is commonly used across conditions presenting with acute episodes for pain and fever following minor procedures, injuries, or routine immunizations, particularly in pediatric patients. It is considered relevant in contexts involving heightened systemic burden for diverse patient groups. This supportive therapeutic benefit contributes to easing the overall symptom load.


Quick Fact: Support for Acute Symptomatic Periods
Paracetamol Polpharma is commonly used when symptoms intensify and supportive relief is needed for non-severe pain and fever.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Paracetamol Polpharma — Official Regulatory Information


Eligibility Scope

Classification Population Eligibility Rules (Regulatory Wording Only)
Populations Allowed Adults, the elderly, and adolescents 16 years and over are generally eligible for use. May be used during pregnancy if clinically needed (lowest dose, shortest time, lowest frequency). Not contraindicated during lactation [Source 1.1].
Populations Contraindicated Absolute prohibition for patients with known hypersensitivity to paracetamol or any excipient, or those with severe hepatic impairment or severe active liver disease [Source 1.3].
Age-Related Rules Adults/Elderly require no dose adjustment based on age alone. The medicine is not recommended for children under 10 years of age for certain oral forms [Source 1.1].
Conditional Caution Caution is advised and/or dose reduction is required for patients with severe renal impairment (CrCl le 30 mL/min), mild to moderate hepatic insufficiency, chronic alcoholism, severe hypovolemia (dehydration), and chronic malnutrition [Source 1.2, 1.3]. The risk of overdose is labeled as greater in those with non-cirrhotic alcoholic liver disease [Source 1.2].

Eligibility Classifications (High-Level)

  • Eligibility severity classification (as defined in official documents): Contraindicated (Hypersensitivity, Severe Hepatic Impairment) and Use with Caution/Restriction (Organ Function, Alcoholism).
  • Regulatory basis: Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Resulting Eligibility Structure

The regulatory documentation formally defines two key exclusions: the absolute prohibition for patients with hypersensitivity or severe hepatic impairment. Beyond these contraindications, eligibility is conditional. Restrictions mandate that use proceeds with caution and often requires modified dosing for populations with compromised renal or hepatic function, or those with risk factors like chronic alcoholism.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interaction patterns based on regulatory prescribing information.

Contraindicated Combinations and Restrictions

Co-administration with any other product containing acetaminophen (prescription or nonprescription) is strictly prohibited to prevent exceeding the recommended dose and mitigating the risk of acute liver failure. The consumption of three or more alcoholic drinks per day while using this medicine is also formally documented to significantly increase the risk of severe liver damage.


Pharmacokinetic and Pharmacodynamic Interactions

Interacting Medicine Official Regulatory Outcome
Warfarin (Sodium Warfarin) May potentiate the hypoprothrombinemic effect, leading to a documented increase in International Normalized Ratio (INR).
Cholestyramine Decreases the absorption of paracetamol, which reduces plasma concentration. Labeling requires timing separation—cholestyramine must not be given within one hour of paracetamol.
Antiepileptic Drugs (e.g., Phenytoin, Carbamazepine) Co-administration may increase the risk of hepatotoxicity due to enzyme induction.
Probenecid Inhibits conjugation, which nearly halves the clearance of paracetamol.

Population-Specific Interaction Notes

Paracetamol is contraindicated in patients with Severe Hepatic Impairment or Severe Active Liver Disease, as the underlying condition heightens the risk of acute liver failure from interaction-related toxicity. Patients with severe renal impairment may require caution due to the potential need for adjusted dosing intervals.

Advertisements

Mechanism of Action

How Paracetamol Polpharma Works

Central Inhibition of Key Enzyme Activity

Paracetamol Polpharma primarily acts within the Central Nervous System (CNS), where it interacts with pathways involving the Cyclooxygenase ( COX) enzyme. The mechanism involves inhibiting the synthesis of certain prostaglandins, which function as lipid mediators in nociceptive pathways, consequently influencing the ascending transmission pathways involved in nociception.


Modulation of the Thermoregulatory Center

The antipyretic effect is achieved through action in the hypothalamus, the brain's temperature control center. By limiting the production of prostaglandins (like PGE2) at this central site, the drug helps to adjust the elevated thermoregulatory set-point, permitting the re-engagement of internal mechanisms that promote efferent thermal regulation.


Differential Pathway Selectivity

Paracetamol Polpharma's mechanism demonstrates a differential distribution of COX inhibition, influencing neurochemical signaling predominantly over peripheral inflammatory pathways. This molecular profile restricts the drug's influence on peripheral inflammatory cascades, supporting a targeted adjustment of central enzyme activity.

Advertisements

Dosage and Administration Information

The administration of paracetamol products is governed by clinical guidelines that define dose, frequency, and maximum allowable intake. The medicine is available for oral use (tablets, solutions), rectal use (suppositories), and intravenous use (infusion), with the maximum total daily dose applying across all forms.


Official Dosing and Frequency

Administration Parameter Standard Guidance
Standard Single Dose 500 mg to 1,000 mg (1 g) for adults.
Minimum Dose Interval 4 hours must elapse between administrations.
Maximum Daily Dose 4,000 mg (4 g) in 24 hours (for adults ge 50 kg).

The drug is typically used on an as-needed basis, and the duration of use is typically limited to the shortest time possible, generally not exceeding 3 days for fever or 5 days for pain without medical reassessment.


Administration Requirements

Oral formulations may be taken with or without food; tablets that are dispersible or effervescent must be fully dissolved in water prior to ingestion. Intravenous formulations must be administered only as a 15-minute infusion.

Population-Specific Use

Standard medical labeling requires dose reduction or a prolonged dosing interval in the presence of hepatic or renal impairment. For severe renal impairment, the minimum interval between doses is typically extended to 6 or 8 hours. The use protocol also prohibits concurrent administration with any other product containing paracetamol, ensuring the maximum daily dose is not inadvertently exceeded.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Paracetamol Polpharma

This overview describes the types of research, the main findings observed in patient groups, and the areas where evidence remains limited or uncertain for the use of paracetamol, the active ingredient in Paracetamol Polpharma. The information is based on official regulatory and scientific reviews of clinical trials.


Evidence for Acute Mild-to-Moderate Pain and Headache

Research has primarily focused on observations in patients experiencing outcomes related to acute physical discomfort, such as the general mild-to-moderate pain following minor surgical or dental procedures. These studies are typically short-term Randomized Controlled Trials (RCTs) that examine populations of healthy adults or post-operative patients. Researchers applied these study designs exploring how symptoms change over time and monitored patient-reported outcomes describing perceived discomfort.

Studies report how symptoms evolved in the observed populations, describing patterns of measured outcomes related to pain intensity compared to a control group over the immediate few hours following a single administration. The available research in this area consists predominantly of short-term RCTs and systematic reviews. For episodic tension-type headaches, the evidence base contributes to understanding these short-term symptom patterns through research exploring short-term symptom changes.


Evidence for Fever Reduction (Antipyresis)

The research exploring antipyresis consists mainly of RCTs and associated Meta-analyses. These studies were applied in research contexts involving temporary physiological imbalance and monitored outcomes linked to systemic or functional imbalance, such as the absolute change in body temperature. The populations studied included febrile children, often following routine immunizations, and some febrile adults.

Studies report how symptoms evolved in the observed populations, describing patterns of measured outcomes related to decreased body temperature, typically within a few hours following administration, particularly in pediatric groups. Studies consistently reported measured changes in body temperature when examining short-term symptom patterns.


What is Still Uncertain About Paracetamol Research

A key limitation is the modest effect size reported for some uses, such as in chronic osteoarthritis pain, despite the high volume of research. Research is ongoing to clarify the role of observations in chronic pain settings, as the follow-up durations were limited in most intervention trials. The evidence quality may vary across studies, and findings were mixed in contexts like measured outcomes for fever reduction in critically ill patients, where the certainty remains low.

Additionally, subgroup findings are uncertain, meaning research does not determine whether an individual with a specific health background will respond similarly to the group patterns observed in the studies. This research provides context but not individual predictions for all possible observations and patient types.

Key Studies & References The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Paracetamol Polpharma (FAQ)


Q: Does Paracetamol Polpharma start working immediately?

Official information describes that the medicine is generally absorbed rapidly after you take it. The amount of the medicine in the blood typically reaches its peak level within 30 to 60 minutes, which provides context for when the effects may begin.


Q: How long does the pain relief from Paracetamol Polpharma last?

Regulatory documents describe the duration of the pain-relieving effect as lasting for approximately 4 to 5 hours. This described duration aligns with the general timing considerations for administration intervals.


Q: Can Paracetamol Polpharma cause stomach upset?

Official product information states that at recommended doses, paracetamol does not typically cause irritation to the stomach or digestive system. However, specific side effects such as nausea and vomiting are documented in the undesirable effects section of regulatory labeling.


Q: Is it possible to take Paracetamol Polpharma while using herbal supplements?

Official guidance indicates that paracetamol is not usually affected by taking general herbal remedies or supplements. However, it is noted that these products are typically not tested for interactions in the same way as prescription medicines.


Q: Can you take Paracetamol Polpharma for a headache that comes back often?

The medicine is officially indicated for the symptomatic relief of various headaches. Regulatory advice states that use should not continue for longer than three days without a medical consultation. Patients can seek consultation if their headaches become persistent.


Q: Do studies confirm the effectiveness of Paracetamol Polpharma for fever?

Yes, official regulatory documents classify the medicine as an antipyretic, which means it reduces fever. Its effectiveness for fever reduction has been established through clinical research.


Q: How quickly should I expect to see an effect after taking Paracetamol Polpharma?

Official documents describe that the pain-relieving effect often begins around 30 minutes after administration. The maximal therapeutic effect is typically reached within one to two hours, and the latency of effect is often observed within this timeframe.


Q: What do official documents say about using Paracetamol Polpharma during pregnancy?

Official information states that paracetamol can be used during pregnancy if a healthcare provider deems it clinically necessary. Regulatory advice is to use the lowest effective dose for the shortest possible duration and frequency.


Q: What are the general recommendations for the maximum duration of use for Paracetamol Polpharma?

Regulatory guidance advises that the medicine should not be used for longer than three days for fever or five days for pain without speaking to a physician. This is a regulatory constraint that limits continuous use.


Q: Can Paracetamol Polpharma interact with over-the-counter cold medicines?

Yes, regulatory documentation strictly prohibits using this medicine with any other product that contains paracetamol. Many over-the-counter cold and flu preparations contain paracetamol as an active ingredient, and combining them creates a risk of exceeding the recommended limits, which can be harmful.


Q: Are allergic reactions to Paracetamol Polpharma common?

The official safety profile states that most adverse effects of paracetamol are generally rare. Hypersensitivity (allergic reactions) and serious skin reactions are formally reported as Very Rare occurrences.


Q: What is the official guidance for Paracetamol Polpharma use during breastfeeding?

Official product information indicates that while the active ingredient does pass into breast milk, the risk of it affecting the nursing child is generally considered unlikely when the medicine is used at therapeutic doses.


Q: What information is available about potential kidney effects from Paracetamol Polpharma?

Official regulatory documents mention that severe kidney adverse events have been reported, particularly with the long-term use of very high doses. Regulatory constraints indicate a need for adjusted use in the presence of pre-existing kidney impairment.


Q: Why is the mechanism of action of paracetamol sometimes described as 'not fully understood'?

Official documents describe the mechanism as involving the inhibition of specific enzymes, similar to aspirin, though with a selective action. This selectivity and the drug's effects on different pathways suggest a complexity that has been described in scientific literature as not fully elucidated.


Q: Is Paracetamol Polpharma used for managing muscle pain?

Yes, official regulatory indications state that the medicine is formally used for the symptomatic relief of various aches and pains, including general muscle pain.


Q: Is Paracetamol Polpharma used for inflammatory pain?

Regulatory documents indicate the medicine is used for the symptomatic relief of pain, which includes rheumatic aches, but its primary effect is not peripheral anti-inflammatory action.


Q: Does Paracetamol Polpharma have any impact on sleep patterns?

Official product information does not typically list effects on sleep at therapeutic doses. However, sedation is mentioned as a possible effect in the context of an overdose.


Q: Can children take Paracetamol Polpharma?

Official labeling contains specific dosing tables for children of various ages, including infants from three months and older, when necessary for pain and fever. Specific use requires adherence to the official weight- and age-based guidance defined in product labeling.


Q: Is Paracetamol Polpharma appropriate for older adults?

Official instructions specify that adults, including the elderly, are generally eligible for use. Dose adjustments or interval changes are typically only necessary if the person has kidney or liver impairment, when necessary due to compromised organ function.


Q: Can Paracetamol Polpharma affect my ability to drive?

Official information explicitly states that paracetamol has no or negligible influence on the ability to drive or operate machinery at recommended doses.


Q: Does Paracetamol Polpharma contain gluten or common allergens?

The complete list of all ingredients and excipients is available in the official product labeling (SmPC). Patients can review this list to check for the presence of specific substances like gluten or other common allergens.


Q: Does Paracetamol Polpharma affect blood pressure?

Official regulatory documents list low blood pressure as a possible side effect, though it is not classified in the Common or Very Common categories of adverse reactions.


Q: What does official research say about the appropriate dosage intervals for Paracetamol Polpharma?

The minimum dose interval of four hours is a regulatory requirement established to prevent accumulation and toxicity. The underlying research supports this by showing the drug's plasma half-life is approximately two hours.


Q: Are there different strengths of Paracetamol Polpharma available?

Yes, official documents describe different formulations, including oral and intravenous forms, with various strengths. Examples include single-unit doses of 500 mg and 1,000 mg.


Q: Are there any known interactions between Paracetamol Polpharma and vitamin supplements?

Official guidance mentions that paracetamol is generally not affected by common vitamin supplements. Official documentation notes that health history should include all supplements and medicines used.


Q: Is it true that Paracetamol Polpharma is generally well-tolerated?

Yes, official regulatory documents describe paracetamol as a generally well-tolerated medicine for patients. This statement is supported by the fact that most adverse effects are officially classified as rare.


Q: What is the role of Paracetamol Polpharma in managing post-operative pain?

Paracetamol is officially indicated for the relief of mild to moderate pain. This includes use in a post-operative setting where an intravenous or other route of administration may be deemed necessary by a clinician.


Q: Can Paracetamol Polpharma be taken by someone with high blood sugar?

Official sources note that paracetamol may potentially interfere with continuous glucose monitoring (CGM) systems. This interference could result in falsely high glucose readings for those relying on CGM devices, and Official sources describe a need for careful consideration for patients using CGM devices.


Q: What is the official classification of Paracetamol Polpharma in terms of safety?

Paracetamol is officially classified as an analgesic (pain reliever) and antipyretic (fever reducer). It belongs to the non-opioid pharmacological group, which is the classification used in official documents.

Advertisements

How should Paracetamol Polpharma be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of this medicine are strictly defined by regulatory labeling to maintain product stability and ensure public safety.

Scope Element Official Regulatory Requirement
Storage Conditions Store at room temperature, typically below 25 C or 30 C, protected from excess heat, light, and moisture (FDA, EMA).
Handling Constraints Do not store in the bathroom or in any location where the product could freeze or be subjected to high humidity (MedlinePlus, EMA).
Packaging Keep the medicine in its original container and ensure the container is tightly closed to preserve integrity (MedlinePlus).
Child Protection A mandatory instruction is to keep the product out of the sight and reach of children (FDA, TGA).
Product Disposal Do not throw away medicines via wastewater or regular household waste. The preferred method is to return unused or expired product to a drug take-back program or pharmacy for proper disposal (FDA, EMA).

These official statements ensure the product's quality remains consistent until the expiration date and detail the regulated procedures for safe environmental disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paracetamol Polpharma found in:

A-Z Index: